GlassScriptPhysician profile
Steven Kozmary
NPI 1659337459
$3,239.93
in general payments reported to CMS, 2019-2025
38 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $174 · 2021: $451 · 2022: $663 · 2023: $415 · 2024: $145 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $748.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $906.15 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.75 | 2019-2023 | Relistor |
| Forte Bio-Pharma LLC | $291.01 | 2020-2024 | Prolate, Nalocet |
| Stimwave Technologies Incorporated | $200.43 | 2019 | |
| Medtronic, INC. | $154.63 | 2021-2025 | Inceptiv, Intellis Adaptivestim |
| Sentynl Therapeutics, INC. | $141.18 | 2019 | |
| Abbvie INC. | $140.47 | 2022-2025 | |
| Piramal Critical Care | $113.42 | 2022-2024 | |
| Pfizer INC. | $109.53 | 2019-2023 | |
| Amgen INC. | $73.63 | 2019 | |
| Impel Pharmaceuticals INC. | $67.26 | 2023 | Trudhesa |
| Biohaven Pharmaceuticals, INC. | $52.47 | 2021 | |
| Si-Bone, INC. | $49.94 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $45.42 | 2019-2020 | |
| Indivior INC. | $45.40 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $42.55 | 2019-2023 | Ztlido |
| Arbor Pharmaceuticals, INC. | $39.85 | 2020-2021 | |
| Tersera Therapeutics LLC | $37.78 | 2019-2023 | Prialt |
| Flowonix Medical Incorporated | $30.37 | 2019 | |
| Allergan, INC. | $28.02 | 2019 | |
| Assertio Therapeutics, INC. | $24.84 | 2019 | |
| Depuy Synthes Sales INC. | $24.11 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.16 | 2019 | |
| Ibsa Pharma INC. | $22.97 | 2023 | Tirosint, Licart |
| Zyla Life Sciences, INC. | $22.71 | 2019-2020 | |
| Eisai INC. | $22.29 | 2020 | |
| Mdd US Operations, LLC | $21.92 | 2019 | |
| Daiichi Sankyo INC. | $20.03 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $19.20 | 2025 | |
| Alkermes, INC. | $18.82 | 2019 | |
| Hikma Pharmaceuticals USA | $16.13 | 2022 | |
| Biotronik Nro, INC. | $15.43 | 2025 | Prospera |
| Medtronic USA, INC. | $15.36 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.90 | 2019 | |
| Boston Scientific Corporation | $14.85 | 2019 | |
| Lilly USA, LLC | $14.68 | 2020 | |
| Idorsia Pharmaceuticals US INC | $12.93 | 2023 | Quviviq |
| Vertical Pharmaceuticals, LLC | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Kozmary listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.